{"contacts": [{"terms": [{"accession": "MS:1002037", "name": "dataset submitter"}, {"accession": "MS:1000586", "name": "contact name", "value": "Bogdan Budnik"}, {"accession": "MS:1000589", "name": "contact email", "value": "bbudnik@mcb.harvard.edu"}, {"accession": "MS:1000590", "name": "contact affiliation", "value": "Harvard University"}]}, {"terms": [{"accession": "MS:1002332", "name": "lab head"}, {"accession": "MS:1000586", "name": "contact name", "value": "David J Mooney"}, {"accession": "MS:1000589", "name": "contact email", "value": "mooneyd@seas.harvard.edu"}, {"accession": "MS:1000590", "name": "contact affiliation", "value": "Harvard John A. Paulson School of Engineering and Applied Sciences"}]}], "description": "We have developed a composite infection vaccine technology (ciVAX) assembled from approved products for rapid response to pandemics and biothreat agents. ciVAX consists of an injectable biomaterial scaffold containing factors that recruit, reprogram and release dendritic cells (DC) in vivo. For bacterial infections, ciVAX contains Fc-Mannose-Binding Lectin (FcMBL) microbeads with captured PAMPs fractions from inactivated bacterial cell-wall lysates. ciVAX vaccination generates potent humoral and T cell responses to bacterial antigens, and ciVAX protects mice and pigs against lethal E coli challenge in sepsis and septic shock models", "fullDatasetLinks": [{"accession": "MS:1002488", "name": "MassIVE dataset URI", "value": "http://massive.ucsd.edu/ProteoSAFe/dataset.jsp?task=a8045907815c4312b614d4385a2fd67d"}, {"accession": "MS:1002852", "name": "Dataset FTP location", "value": "ftp://massive.ucsd.edu/MSV000086751/"}], "identifiers": [{"accession": "MS:1002487", "name": "MassIVE dataset identifier", "value": "MSV000086751"}, {"accession": "MS:1001919", "name": "ProteomeXchange accession number", "value": "PXD023763"}, {"accession": "MS:1001921", "name": "ProteomeXchange accession number version number", "value": "1"}], "instruments": [{"accession": "MS:1002732", "name": "Orbitrap Fusion Lumos"}], "keywords": [{"accession": "MS:1001925", "name": "submitter keyword", "value": "composite infection vaccine technology (ciVAX), Fc-Mannose-Binding Lectin (FcMBL) microbeads, T cell responses to bacterial antigens"}], "modifications": [{"accession": "UNIMOD:35", "name": "Oxidation"}, {"accession": "UNIMOD:7", "name": "Deamidated"}, {"accession": "UNIMOD:4", "name": "Carbamidomethyl"}], "publications": [{"terms": [{"accession": "MS:1002853", "name": "Dataset with no associated published manuscript"}]}], "species": [{"terms": [{"accession": "MS:1001469", "name": "taxonomy: scientific name", "value": "Escherichia coli"}, {"accession": "MS:1001468", "name": "taxonomy: common name", "value": "E. coli"}, {"accession": "MS:1001467", "name": "taxonomy: NCBI TaxID", "value": "562"}]}, {"terms": [{"accession": "MS:1001469", "name": "taxonomy: scientific name", "value": "Staphylococcus aureus"}, {"accession": "MS:1001467", "name": "taxonomy: NCBI TaxID", "value": "1280"}]}], "title": "Modular biomaterials vaccine technology protects against multiple pathogens and septic shock"}